Tiffany Schwasinger-Schmidt, MD
Internal Medicine · Huntsville, ALNPI 1598178436
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (55.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Shionogi Inc at 39.0% of the total. Among internal medicine clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 51 payments — averaging $160.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shionogi Inc$3K
- Janssen Research & Development, LLC$2K
- Eisai Inc.$2K
- Boehringer Ingelheim$1K
- Viiv Healthcare Company$60
- E.r. Squibb & Sons, L.L.C.$51
- plus $189 from 6 others
Across 207 payments — averaging $3767.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$448K
- Janssen Research & Development, LLC$114K
- Boehringer Ingelheim$68K
- Sage Therapeutics, LLC$37K
- Bristol Myers Squibb$27K
- Astrazeneca UK Limited$20K
- plus $66K from 8 others
What the payments were for
- Consulting fees$2,08025%
- Travel & lodging$4,57456%
- Food & beverage$1,54819%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shionogi Inc | 4 | $3,199 |
| Janssen Research & Development, LLC | 19 | $1,849 |
| Eisai Inc. | 9 | $1,788 |
| Boehringer Ingelheim | 4 | $1,066 |
| Viiv Healthcare Company | 3 | $60 |
| E.r. Squibb & Sons, L.L.C. | 1 | $51 |
| Lundbeck LLC | 1 | $44 |
| AbbVie | 3 | $39 |
| Lilly USA, LLC | 2 | $30 |
| Johnson & Johnson | 2 | $30 |
| Novo Nordisk | 2 | $29 |
| GSK | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,202 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 70 | $53,008 |
| OzempicSemaglutide | 32 | $32,199 |
| EliquisApixaban | 32 | $25,744 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 56 | $16,939 |
| TrulicityDulaglutide | 14 | $15,082 |
| FarxigaDapagliflozin Propanediol | 14 | $10,810 |
| Repatha SyringeEvolocumab | 12 | $6,616 |
| Pregabalin | 36 | $4,248 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 18 | $3,864 |
| Ursodiol | 15 | $1,723 |
| Omeprazole | 121 | $1,276 |
| Atorvastatin Calcium | 172 | $1,033 |
| Levothyroxine Sodium | 139 | $909 |
| Duloxetine Hcl | 17 | $907 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $1,066 | $53,00870 claims |
| Novo NordiskOzempic | $29 | $32,19932 claims |
| GSKArexvy, Shingrix | $17 | $20,80374 claims |
| Lilly USA, LLCTrulicity | $30 | $15,08214 claims |
| AbbVieArmour Thyroid | $39 | $74511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Huntsville
- Joseph HastieHuntsville$44K
- Vytautas PukisHuntsville$16K
- Tanja DudenbostelHuntsville$14K
- Ryan WeldonBirmingham$458K
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Robert LewisBirmingham$187K
- Rosalind BowlesGadsden$168K
- Sonja PettusJasper$117K
- Bobby WrightsMobile$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.